A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants.
In: Hepatitis Weekly, 2024-04-15, S. 343-343
serialPeriodical
Zugriff:
This document provides information about a clinical trial conducted by DICE Therapeutics, Inc., a subsidiary of Eli Lilly and Company. The trial, NCT06345794, aims to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on the single-dose pharmacokinetics of LY4100511 (DICE-853) in healthy participants. The study also intends to evaluate the safety and tolerability of LY4100511 (DICE-853) when coadministered with these medications. The trial is in the interventional phase and is designed as a single-center, open-label, 3-cohort, fixed-sequence, drug-drug interaction study. It is not yet recruiting participants and is expected to be completed by June 17, 2024. [Extracted from the article]
Copyright of Hepatitis Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants.
|
---|---|
Zeitschrift: | Hepatitis Weekly, 2024-04-15, S. 343-343 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1086-0223 (print) |
Schlagwort: |
|
Sonstiges: |
|